The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 9 of the 30 sources its claims cite were checked for support.
The Human Proteoform Project: Defining the human proteome
Open accessAbstract
An ambitious initiative is proposed to generate a definitive reference set of human proteoforms.
Overview
CoChat Summary
## TL;DR
The paper is a roadmap/proposal for the Human Proteoform Project, arguing that understanding biology and disease requires a comprehensive reference atlas of human proteoforms, not just genome sequence. It proposes a two-pronged strategy: deep proteoform analysis in medically relevant systems and large-scale technology development for proteoform discovery and characterization.
## Key findings
- The authors argue that the human proteome should be defined as the set of all proteoforms expressed by an organism, because proteins from a single gene can vary through genetic variation, alternative splicing, and PTMs.
- They propose an atlas-building strategy centered on two paths: global studies of detectable proteoforms and targeted studies of proteoform families from each human gene.
- The paper gives explicit scale estimates for the project: assuming 5,000 cell types and a depth of 1 million proteoforms in each, the Human Proteoform Atlas would involve about 5 billion measurements of redundant proteoforms; combined with the gene-based approach, it anticipates about 50 million unique (nonredundant) proteoforms with defined quality metrics.
- It notes that current bottom-up proteomics remains limited: the aggregated NCI-60 dataset covers only 12% of the whole encoded proteome, only about 5% of genes had >50% sequence coverage of their protein-coding regions, and detection of alternative splice forms remains very limited (<0.1% of putative novel splice junctions in cancer xenografts).
## Methods
- Not an empirical study; this is a perspective/proposal article laying out a conceptual framework and roadmap for the Human Proteoform Project.
- The proposed design combines cell-based proteoform discovery across defined human cell types with a gene-based targeted approach using affinity reagents to enrich proteoform families.
- The main analysis is argumentative and strategic: it synthesizes existing proteomics limitations, compares top-down and bottom-up approaches, and uses rough scale estimates to motivate technology development and atlas construction.
## Limitations
- The paper states that today’s ability to comprehensively identify proteoforms in complex systems is limited, and that top-down proteomics is powerful but still limited in depth and throughput.
- It explicitly says the project will necessarily focus on capturing the dominant functional proteoform population rather than rare occurrences.
- Evident from the text: the paper does not present new experimental data or validate the proposed atlas; its estimates and goals are forward-looking projections rather than results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
6 Valid · 2 Not valid · 13 Not checked · 14 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“At present, the dominant “bottom-up” paradigm of mass spectrometry (MS)–based proteomics sacrifices information about proteoforms by cleaving proteins into peptides; this is done for a pragmatic reason—it works, as the resultant peptides are generally much easier to identify than their parent intact proteoforms ( 8 , 9 ).”
What the sources say
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genetic variation, alternative splicing, and posttranslational modification (PTM) work together to create a rich variety of different proteoforms arising from our genes ( Fig. 1 ) ( 3 ).”
What the sources say
- Supportedcites [3] source
In “To the Editor,” the paper says protein complexity arises from allelic variation, alternative RNA splicing, and post-translational modifications. It then defines proteoforms as the different molecular forms of a single gene’s protein product, including forms produced by all three mechanisms (Fig. 1). (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Proteins are the central intermediaries between genotype and phenotype ( 2 – 4 ).”
What the sources say
- Not checked yetcites [2] source
- Supportedcites [3] source
In “To the Editor” (page not specified), the paper links genetic and RNA variation to distinct protein molecules, then says those molecules modulate a wide variety of biological processes. That supports the broad description of proteins as intermediaries between genotype and phenotype. (LLM, conf=0.85)
- Supportedcites [4] source
The Abstract (p. 3) describes proteins as deeply involved in the major processes of life and occupying the space between human genetics and diverse phenotypes. This supports the citing sentence’s paraphrase. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While today’s mass spectrometric platforms are pushing toward detection limits of ~25 copies per cell ( 7 ),”
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
Our copy does address mass-spectrometric detection sensitivity at the per-cell copy-number level, but the only threshold it gives is a project requirement, not a current capability: 'A cell-based Human Proteome Project places a premium on defining and isolating specific cell types prior to analysis with 100 % sequence coverage for proteoforms detected at a copy number of 10 and above' (Discussion > Defining the Proteome of Specific Cell Types). Nowhere in the paper is a '~25 copies per cell' detection limit stated, nor is any figure attributed to 'today's mass spectrometric platforms' current push; the nearby numbers (~10,000 expressed proteins detectable from a single human cell type, ~250,000 detectable proteoforms per cell type, <20 % sequence-space coverage of mainstream technologies) concern protein/proteoform counts and coverage, not copies-per-cell limits. So the direction of the claim (MS sensitivity approaching low copy numbers per cell) is in the source, but the specific ~25 value and its framing as present-day capability are not supported. (LLM, conf=0.62)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The depth of proteoform analysis obtained depends on the detection sensitivity of the technology used:”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 35 claims and to verify the 21 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A full characterization of protein variability also remains a major technical challenge, since the approximately 20,300 human coding genes can produce hundreds of thousands of protein variants through alternative splicing and posttranslational modification (PTM) (129, 130).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [129]
Experimental — accuracy not yet measured
Citations
Cites
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
A subcellular map of the human proteome
Thul, P. J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Björk, L., Breckels, L. M., et al. (2017) · Science · doi:10.1126/science.aal3321 · Cited by 2,813 · cited 2×
“Prior initiatives such as those describing first drafts of the human proteome in 2014 (33, 34) and ongoing work under the aegis of the Human Protein Atlas and the Human Proteome Project (35) have accomplished a great deal over the past several years, and the Human Proteome Organization has called for the community to…”
MethodEcosystem as Structure: An Actionable Construct for Strategy
Adner, R. (2017) · Journal of Management · doi:10.1177/0149206316678451 · Cited by 2,600
Mass-spectrometric exploration of proteome structure and function
Aebersold, R., & Mann, M. (2016) · Nature · doi:10.1038/nature19949 · Cited by 2,334 · cited 1×
“NEW TECHNOLOGIES At present, the dominant “bottom-up” paradigm of mass spectrometry (MS)–based proteomics sacrifices information about proteoforms by cleaving proteins into peptides; this is done for a pragmatic reason—it works, as the resultant peptides are generally much easier to identify than their parent intact p…”
BackgroundRegev, A., Teichmann, S. A., Lander, E. S., Amit, I., Benoist, C., Birney, E., Bodenmiller, B., Campbell, P., Carninci, P., Clatworthy, M., et al. (2017) · eLife · doi:10.7554/elife.27041 · Cited by 2,232
A draft map of the human proteome
Kim, M.-S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Chaerkady, R., Madugundu, A. K., Kelkar, D. S., Isserlin, R., Jain, S., et al. (2014) · Nature · doi:10.1038/nature13302 · Cited by 2,198
Mass-spectrometry-based draft of the human proteome
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A. M., Lieberenz, M., Savitski, M. M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014) · Nature · doi:10.1038/nature13319 · Cited by 1,820 · cited 1×
“Prior initiatives such as those describing first drafts of the human proteome in 2014 (33, 34) and ongoing work under the aegis of the Human Protein Atlas and the Human Proteome Project (35) have accomplished a great deal over the past several years, and the Human Proteome Organization has called for the community to…”
MethodA vision for the future of genomics research
Collins, F. S., Green, E. D., Guttmacher, A. E., Guyer, M. S., & on behalf of the US National Human Genome Research Institute (2003) · Nature · doi:10.1038/nature01626 · Cited by 1,752 · cited 3×
“Proteins are primary effectors of function in biology, and thus, complete knowledge of their structure and behavior is fundamental to deciphering function in basic and translational research (2).”
BackgroundMethodProteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Proteoform: a single term describing protein complexity
The Consortium for Top Down Proteomics, Smith, L. M., & Kelleher, N. L. (2013) · Nature Methods · doi:10.1038/nmeth.2369 · Cited by 1,528
Self-citation
Cited by
Novel Strategies to Address the Challenges in Top-Down Proteomics
Melby, J. A., Roberts, D. S., Larson, E. J., Brown, K. A., Bayne, E. F., Jin, S., & Ge, Y. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.1c00099 · Cited by 190
Self-citationConnecting aging biology and inflammation in the omics era
Walker, K. A., Basisty, N., Wilson, D. M., & Ferrucci, L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158448 · Cited by 189
“A full characterization of protein variability also remains a major technical challenge, since the approximately 20,300 human coding genes can produce hundreds of thousands of protein variants through alternative splicing and posttranslational modification (PTM) (129, 130).”
BackgroundGlobal detection of human variants and isoforms by deep proteome sequencing
Sinitcyn, P., Richards, A. L., Weatheritt, R. J., Brademan, D. R., Marx, H., Shishkova, E., Meyer, J. G., Hebert, A. S., Westphall, M. S., Blencowe, B. J., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01714-x · Cited by 182
“Thus, sequence coverage in a proteomics experiment is generally insufficient to fully characterize all protein states present within a sample 21,22 .”
BackgroundRoberts, D. S., Loo, J. A., Tsybin, Y. O., Liu, X., Wu, S., Chamot-Rooke, J., Agar, J. N., Paša-Tolić, L., Smith, L. M., & Ge, Y. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00318-2 · Cited by 161
Self-citationThe Blood Proteoform Atlas: A reference map of proteoforms in human hematopoietic cells
Melani, R. D., Gerbasi, V. R., Anderson, L. C., Sikora, J. W., Toby, T. K., Hutton, J. E., Butcher, D. S., Negrão, F., Seckler, H. S., Srzentić, K., et al. (2022) · Science · doi:10.1126/science.aaz5284 · Cited by 140
Self-citationTen Years of Extracellular Matrix Proteomics: Accomplishments, Challenges, and Future Perspectives
Naba, A. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100528 · Cited by 126
“The recognition of proteoform diversity is not recent (140), neither is the recognition of the need to profile proteoforms (141, 142).”
BackgroundTop-Down Proteomics and the Challenges of True Proteoform Characterization
Po, A., & Eyers, C. E. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00416 · Cited by 121
Single-cell proteomics takes centre stage
Perkel, J. M. (2021) · Nature · doi:10.1038/d41586-021-02530-6 · Cited by 92
Yang, M., Unsihuay, D., Hu, H., Meke, F. N., Qu, Z., Zhang, Z., & Laskin, J. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04795 · Cited by 97
McCool, E. N., Xu, T., Chen, W., Beller, N. C., Nolan, S. M., Hummon, A. B., Liu, X., & Sun, L. (2022) · Science Advances · doi:10.1126/sciadv.abq6348 · Cited by 95
Plubell, D. L., Käll, L., Webb-Robertson, B.-J., Bramer, L. M., Ives, A., Kelleher, N. L., Smith, L. M., Montine, T. J., Wu, C. C., & MacCoss, M. J. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00894 · Cited by 85
Self-citationEngineering Biological Nanopore Approaches toward Protein Sequencing
Wei, X., Penkauskas, T., Reiner, J. E., Kennard, C., Uline, M. J., Wang, Q., Li, S., Aksimentiev, A., Robertson, J. W. F., & Liu, C. (2023) · ACS Nano · doi:10.1021/acsnano.3c05628 · Cited by 88
Suskiewicz, M. J. (2024) · BioEssays · doi:10.1002/bies.202300178 · Cited by 110
“[99,100] It has beenproposed that such diversity could explain the stunningcomplexityofthehumanorganism,whichisdifficulttosquare with the limited gene number.”
BackgroundChemical Synthesis of Human Proteoforms and Application in Biomedicine
Ai, H., Pan, M., & Liu, L. (2024) · ACS Central Science · doi:10.1021/acscentsci.4c00642 · Cited by 77
High sensitivity top–down proteomics captures single muscle cell heterogeneity in large proteoforms
Melby, J. A., Brown, K. A., Gregorich, Z. R., Roberts, D. S., Chapman, E. A., Ehlers, L. E., Gao, Z., Larson, E. J., Jin, Y., Lopez, J. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2222081120 · Cited by 73
Self-citationRoles of E3 Ubiquitin Ligases in Plant Responses to Abiotic Stresses
Wang, S., Lv, X., Zhang, J., Chen, D., Chen, S., Fan, G., Ma, C., & Wang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042308 · Cited by 65
“This also highlights the prevalence of ubiquitinated proteins in the proteome as a major proteoform [9,10].”
BackgroundFerdosi, S., Stukalov, A., Hasan, M., Tangeysh, B., Brown, T. R., Wang, T., Elgierari, E. M., Zhao, X., Huang, Y., Alavi, A., et al. (2022) · Advanced Materials · doi:10.1002/adma.202206008 · Cited by 73
Mitochondrial proteome research: the road ahead
Baker, Z. N., Forny, P., & Pagliarini, D. J. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00650-7 · Cited by 70
“PTMs or alternative splicing 58 .”
A roadmap for the functional annotation of protein families: a community perspective
de Crécy‐Lagard, V., Amorín, R., Arighi, C. N., Babor, J. T., Bateman, A. G., Blaby, I. K., Blaby, C., Bridge, A. J., Burley, S. K., Cleveland, S., et al. (2022) · Database · doi:10.1093/database/baac062 · Cited by 66
“Sheynkman finished by discussing the challenges of annotation for not only isoforms but for all proteoforms, including post-translational modifications (113), each of which will likely become increasingly significant given the advances of HTP top-down proteomics technologies (114) and the possibilities of a Human Prot…”
BackgroundThe 2022 Report on the Human Proteome from the HUPO Human Proteome Project
Omenn, G. S., Lane, L., Overall, C. M., Pineau, C., Packer, N. H., Cristea, I. M., Lindskog, C., Weintraub, S. T., Orchard, S. E., Roehrl, M. H. A., et al. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00498 · Cited by 65
Mapping the Proteoform Landscape of Five Human Tissues
Drown, B., Jooß, K., Melani, R. D., Lloyd-Jones, C., Camarillo, J. M., & Kelleher, N. L. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00034 · Cited by 56
Self-citationProteoform‐Selective Imaging of Tissues Using Mass Spectrometry**
Yang, M., Hu, H., Su, P., Thomas, P. M., Camarillo, J. M., Greer, J. B., Early, B. P., Fellers, R. T., Kelleher, N. L., & Laskin, J. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202200721 · Cited by 54
Self-citationXu, T., Wang, Q., Wang, Q., & Sun, L. (2024) · Analytical Methods · doi:10.1039/d4ay00651h · Cited by 56
Deep thermal profiling for detection of functional proteoform groups
Kurzawa, N., Leo, I. R., Stahl, M. M. S., Kunold, E., Becher, I., Audrey, A., Mermelekas, G., Huber, W. K., Mateus, A., Savitski, M. M., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01284-8 · Cited by 50
Integrin signalling in joint development, homeostasis and osteoarthritis
Miao, M. Z., Lee, J. S., Yamada, K. M., & Loeser, R. F. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01130-8 · Cited by 58
Top-down mass spectrometry of native proteoforms and their complexes: a community study
Habeck, T., Brown, K. A., Soye, B. J. D., Lantz, C., Zhou, M., Alam, N., Hossain, M. A., Jung, W., Keener, J. E., Volný, M., et al. (2024) · Nature Methods · doi:10.1038/s41592-024-02279-6 · Cited by 58
“In 2021, the Human Proteoform Project was conceived, with the ambitious goal of producing a high-quality atlas of human proteoforms 10 .”
Self-citationBreckels, L. M., Hutchings, C., Ingole, K. D., Kim, S. Y., Lilley, K. S., Makwana, M. V., McCaskie, K. J. A., & Villanueva, E. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.08.008 · Cited by 46
The Human Proteoform Atlas: a FAIR community resource for experimentally derived proteoforms
Hollas, M. A. R., Robey, M. T., Fellers, R. T., LeDuc, R. D., Thomas, P. M., & Kelleher, N. L. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1086 · Cited by 41
“Associated with the Human Proteoform Project (49–51), proposed by the Consortium for Top-Down Proteomics, we plan to package and adapt an open-source codebase to build robust and scalable proteoform atlases of high-utility.”
Self-citationIdentification of Splice Variants and Isoforms in Transcriptomics and Proteomics
Su, T., Hollas, M. A. R., Fellers, R. T., & Kelleher, N. L. (2023) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-020722-044021 · Cited by 44
“Large-scale funding in this area based on a consortium model may enable the emergence of a clarified solution in this space (124, 125).”
BackgroundSelf-citationNew Views of Old Proteins: Clarifying the Enigmatic Proteome
Burnum-Johnson, K., Conrads, T. P., Drake, R. R., Herr, A. E., Iyengar, R., Kelly, R., Lundberg, E. K., MacCoss, M. J., Naba, A., Nolan, G. P., et al. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100254 · Cited by 42
Self-citationSadeghi, S. A., Ashkarran, A. A., Wang, Q., Zhu, G., Mahmoudi, M., & Sun, L. (2024) · ACS Nano · doi:10.1021/acsnano.4c04675 · Cited by 47
“26 31 − 34 For example, strong evidence has been documented that modifications of a protein [i.e., human serum albumin (HSA)] changing its physico-chemical properties and producing different proteoforms can substantially influence its binding affinity to NPs and the thickness of protein corona on…”
Transforming Chemical Proteomics Enrichment into a High-Throughput Method Using an SP2E Workflow
Becker, T., Wiest, A., Telek, A., Bejko, D., Hoffmann-Röder, A., & Kielkowski, P. (2022) · JACS Au · doi:10.1021/jacsau.2c00284 · Cited by 33
“The incredible diversity of genetic polymorphism, RNA splice variants and PTMs results in many so-called proteoforms (Aebersold et al, 2018; Smith et al, 2019, 2021), which exceed the ~20,000 human genes by approximately fifty times.”
BackgroundZhao, Z., Guo, Y., Chowdhury, T., Anjum, S., Li, J., Huang, L., Cupp‐Sutton, K. A., Burgett, A. W. G., Shi, D., & Wu, S. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01119 · Cited by 31
Liao, Y., Fulcher, J. M., Degnan, D. J., Williams, S. M., Bramer, L., Veličković, D., Zemaitis, K. J., Veličković, M., Sontag, R. L., Moore, R., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100491 · Cited by 32
“Top-down proteomics (TDP) is a mass spectrometry (MS) strategy for characterizing “proteoforms”, which encompass the combination of posttranslational modifications (PTMs), splice-isoforms, and amino acid variants occurring on a protein sequence (1).”
BackgroundSelf-citationModulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms
Röntgen, A., Toprakcioglu, Z., Tomkins, J. E., & Vendruscolo, M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313465121 · Cited by 35
Defining the Sarcomeric Proteoform Landscape in Ischemic Cardiomyopathy by Top-Down Proteomics
Chapman, E. A., Aballo, T. J., Melby, J. A., Zhou, T., Price, S. J., Rossler, K. J., Lei, I., Tang, P. C. Y., & Ge, Y. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00729 · Cited by 32
Self-citationAdvances in the chemical synthesis of human proteoforms
Yang, Z., Xiao, Y., Shi, Y., & Liu, L. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2860-5 · Cited by 33
“…distinct proteins, known as proteoforms (Smith and Kelleher, 2013) — one estimate puts the number of possible proteoforms arising from approximately 20,000 human genes at about 10 7 , many of which are implicated in the onset and progression of disease (Aebersold et al., 2018; Smith et al., 2021).”
Biological mass spectrometry enables spatiotemporal ‘omics: From tissues to cells to organelles
Pade, L. R., Stepler, K. E., Portero, E. P., DeLaney, K., & Nemes, P. (2023) · Mass Spectrometry Reviews · doi:10.1002/mas.21824 · Cited by 30
Native Proteomics by Capillary Zone Electrophoresis‐Mass Spectrometry
Wang, Q., Wang, Q., Qi, Z., Moeller, W. J., Wysocki, V. H., & Sun, L. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202408370 · Cited by 34
Leipert, J., Kaulich, P. T., Steinbach, M. K., Steer, B., Winkels, K., Blurton, C., Leippe, M., & Tholey, A. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202301969 · Cited by 28
Frontiers in mass spectrometry–based clinical proteomics for cancer diagnosis and treatment
Haga, Y., Minegishi, Y., & Ueda, K. (2023) · Cancer Science · doi:10.1111/cas.15731 · Cited by 28
Chen, W., Ding, Z., Zang, Y., & Liu, X. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00207 · Cited by 28
Zhai, Z., Mavridou, D., Damian, M., Mutti, F. G., Schoenmakers, P. J., & Gargano, A. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01760 · Cited by 27
Proteoform medicine: characterizing and targeting protein forms in human disease
Korchak, J. A., Yi, S. S., Kelleher, N. L., Sahni, N., & Sheynkman, G. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00915-1 · Cited by 29
Self-citationLiu, F. C., Ridgeway, M. E., Park, M. A., & Bleiholder, C. (2022) · The Analyst · doi:10.1039/d2an00335j · Cited by 28
Sissala, N., Babačić, H., Leo, I. R., Cao, X., Forshed, J., Eriksson, L. E., Lehtiö, J., Fredolini, C., Åberg, M., & Pernemalm, M. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01753-2 · Cited by 25
“Since different proteoforms can have different cellular functions, localizations, or rolesindisease,measuringthempreciselycanadvancebiomarkerdiscovery anddrugdevelopment 48 .”
α-Synuclein at the Presynaptic Axon Terminal as a Double-Edged Sword
Tan, L. Y., Tang, K. H., Lim, L. Y. Y., Ong, J. X., Park, H., & Jung, S. (2022) · Biomolecules · doi:10.3390/biom12040507 · Cited by 23
Large‐scale top‐down proteomics of the Arabidopsis thaliana leaf and chloroplast proteomes
Wang, Q., Sun, L., & Lundquist, P. K. (2022) · PROTEOMICS · doi:10.1002/pmic.202100377 · Cited by 28
“With the substantial advancements in informatics tools for proteoform identification, such as ProSight [30, 31] and TopPIC suite [32], and the advancement of multi-dimensional separations, numerous TDP experiments have been successfully applied to human and animal samples [33].”
MethodDowling, P., Swandulla, D., & Ohlendieck, K. (2023) · Cells · doi:10.3390/cells12212560 · Cited by 24
Digital Microfluidics for Sample Preparation in Low‐Input Proteomics
Steinbach, M. K., Leipert, J., Matzanke, T., & Tholey, A. (2024) · Small Methods · doi:10.1002/smtd.202400495 · Cited by 23
Uncovering hidden protein modifications with native top-down mass spectrometry
Bennett, J. L., El‐Baba, T. J., Zouboulis, K., Kirschbaum, C., Song, H., Butroid, F. I., Benesch, J. L. P., Lutomski, C. A., & Robinson, C. V. (2025) · Nature Methods · doi:10.1038/s41592-025-02846-5 · Cited by 29
“Distinctly modified protein isoforms (proteoforms) act as unique biological effectors, enabling dynamic control of cellular phenotypes 3,4 .”
Zhang, Y., Cai, Q., Luo, Y., Zhang, Y., & Li, H. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.11.003 · Cited by 24
Seeing the complete picture: proteins in top-down mass spectrometry
Habeck, T., & Lermyte, F. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220098 · Cited by 25
Synthetic Proteins behind the Plasma Barrier: Molecular Spies
Mann, G., Sadhu, P., & Brik, A. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00236 · Cited by 24
Cobley, J. N. (2023) · BioEssays · doi:10.1002/bies.202200248 · Cited by 28
Capillary Electrophoresis–Mass Spectrometry for Top-Down Proteomics
Wang, Q., Wang, Q., Zhu, G., & Sun, L. (2025) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-071124-092242 · Cited by 24
State-of-the-Art and Future Directions in Structural Proteomics
Happonen, L., & Varjosalo, M. T. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101065 · Cited by 21
“Top-down proteomics preserves the integrity of the protein(s) during analysis, hence maintaining critical information about PTMs and proteo-form diversity, which is often lost in bottom-up MS approaches (175).”
Precision cardiovascular medicine: shifting the innovation paradigm
Aikawa, M., Sonawane, A. R., Chelvanambi, S., Asano, T., Halu, A., Matamalas, J. T., Singh, S. A., Uchida, S., Aïkawa, E., Arenas, À., et al. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1474469 · Cited by 27
Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression
Forte, E., Sanders, J. M., Pla, I., Kanchustambham, V. L., Hollas, M. A. R., Huang, C.-F., Sanchez, A., Peterson, K. N., Melani, R. D., Huang, A., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100876 · Cited by 22
Self-citationThe Role of Clinical Glyco(proteo)mics in Precision Medicine
van der Burgt, Y. E. M., & Wuhrer, M. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100565 · Cited by 23
“Despite the fact that each protein can appear in a wide variety of proteoforms, and the proteome consequently contains millions of different structures, it can be argued that a limited number of proteoforms is sufficient to decipher a disease phenotype, that is clinically relevant and has potential for patient stratif…”
BackgroundLiu, F. C., Ridgeway, M. E., Wootton, C. A., Theisen, A., Panczyk, E. M., Meier, F., Park, M. A., & Bleiholder, C. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.3c00187 · Cited by 22
Exploring the unmapped cysteine redox proteoform landscape
Cobley, J. N. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00152.2024 · Cited by 24
Pauper, M., Hentschel, A., Tiburcy, M., Beltrán, S., Ruck, T., Schara, U., & Roos, A. (2025) · Biomolecules · doi:10.3390/biom15010130 · Cited by 18
Guzman, N. A., & Guzman, D. E. (2021) · Biomolecules · doi:10.3390/biom11101443 · Cited by 17
The Promises, Challenges, and Opportunities of Omics for Studying the Plant Holobiont
Carper, D. L., Appidi, M. R., Mudbhari, S., Shrestha, H. K., Hettich, R. L., & Abraham, P. E. (2022) · Microorganisms · doi:10.3390/microorganisms10102013 · Cited by 18
Mass spectrometry-based top-down proteomics for proteoform profiling of protein coronas
Sadeghi, S. A., Fang, F., Nimavard, R. T., Wang, Q., Zhu, G., Saei, A. A., Sun, L., & Mahmoudi, M. (2025) · Nature Protocols · doi:10.1038/s41596-025-01229-6 · Cited by 30
Top-Down Ion Mobility Separations of Isomeric Proteoforms
Berthias, F., Thurman, H. A., Wijegunawardena, G., Wu, H., Shvartsburg, A. A., & Jensen, O. N. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c02948 · Cited by 21
Makey, D. M., Gadkari, V. V., Kennedy, R. T., & Ruotolo, B. T. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00477 · Cited by 21
The role of protein corona in advancing plasma proteomics
Saei, A. A., Sun, L., & Mahmoudi, M. (2024) · PROTEOMICS · doi:10.1002/pmic.202400028 · Cited by 19
Molecular features of human pathological tau distinguish tauopathy-associated dementias
Kumar, M., Schlaffner, C. N., Tang, S., Beuvink, M. A., Viodé, A., Mair, W., Jha, M., Uncu, C., Wesseling, H., Wang, T., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.036 · Cited by 25
“29,30 A large body of research indicates that different patterns of tau post-translational modifications (PTMs) 31–34 and cleavages contribute to heterogeneity of tau structures, 35–37 disease progression, 33,38 and clinical presentation 39 in AD.”
Single-Molecule Enzyme Activity Analysis for Illuminating Pathological Proteoforms
Komatsu, T., & Mizuno, T. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00100 · Cited by 13
Wang, Z., Meng, J., Dai, Q., Li, H., Xia, S., Yang, R., & Luan, Y. (2024) · Expert Systems with Applications · doi:10.1016/j.eswa.2024.124168 · Cited by 15
A peptidoform based proteomic strategy for studying functions of post‐translational modifications
Liu, Y. (2021) · PROTEOMICS · doi:10.1002/pmic.202100316 · Cited by 14
“In this regard, the recent initiative of The Human Proteoform Project is very timely and extremely important for assembling an atlas withmore detailed knowledge by creating a comprehensive proteoform index [34].”
BackgroundAdvancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice
Punetha, A., & Kotiya, D. (2023) · Proteomes · doi:10.3390/proteomes11010002 · Cited by 19
“The physiological and pathological processes may have a varying abundance of a particular proteoform and may exhibit changes in localization or response to stimuli, which makes them highly relevant to intervention and drug discovery in various diseases [5,6].”
BackgroundArcher, E., & Lavie, C. J. (2023) · Behavioral and Brain Sciences · doi:10.1017/s0140525x22002436 · Cited by 14
Papadopoulou, P., & Lytras, M. D. (2023) · Applied Research · doi:10.1002/appl.202200131 · Cited by 15
DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers
Coppedè, F., Bhaduri, U., Stoccoro, A., Nicolì, V., Venere, E. D., & Merla, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411715 · Cited by 12
“However, the central dogma of molecular biology is no longer limited to genes and proteins, rather with the increase in our knowledge of post-translational modifications, astronomical complexity in proteoforms [127] is taking a pivotal role in the functional stage of a protein, the workhorse of a cell.”
BackgroundNimavard, R. T., Sadeghi, S. A., Mahmoudi, M., Zhu, G., & Sun, L. (2025) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.4c00463 · Cited by 14
Spatial top-down proteomics for the functional characterization of human kidney
(2025) · doi:10.1186/s12014-025-09531-x · Cited by 15
“The identity and roles of all proteoforms have yet to be fully characterized, therefore there is a present need to further contextualize which proteoforms effect function [3].”
Self-citationProteoformics: Current status and future perspectives
Fang, Z., Zhang, Y., Feng, X., Li, N., Chen, L., & Zhan, X. (2025) · Journal of Proteomics · doi:10.1016/j.jprot.2025.105524 · Cited by 18
Inside the chase after those elusive proteoforms
Marx, V. (2024) · Nature Methods · doi:10.1038/s41592-024-02170-4 · Cited by 14
Mass spectrometry-based proteomics for source-level attribution after DNA extraction.
Zaarour, L., Padula, M. P., van Oorschot, R. V., & McNevin, D. (2024) · Forensic Science International: Genetics · doi:10.1016/j.fsigen.2024.103168 · Cited by 11
TopPICR: A Companion R Package for Top-Down Proteomics Data Analysis
Martin, E. A., Fulcher, J. M., Zhou, M., Monroe, M. E., & Petyuk, V. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00570 · Cited by 13
Mehlferber, M., Jeffery, E. D., Saquing, J., Jordan, B. T., Sheynkman, L., Murali, M., Genet, G., Acharya, B. R., Hirschi, K. K., & Sheynkman, G. (2022) · RNA Biology · doi:10.1080/15476286.2022.2141938 · Cited by 13
A critical evaluation of ultrasensitive single-cell proteomics strategies
Nalehua, M. R., & Zaia, J. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05171-6 · Cited by 13
“…characterization in biomedicine has shifted from defining the sequence [1, 2] to characterizing protein modifications [3] to identifying proteins in reference to genomics information [4, 5] to quantifying proteins [6, 7] to analyzing protein networks [8, 9] and identifying proteoforms [10, 11].”
Intact Proteoform Analysis by Capillary Electrophoresis–Mass Spectrometry. Are We There Yet?
Gould, N., Wang, Q., Agar, J. N., Brodbelt, J. S., Chen, D., Cupp‐Sutton, K. A., Domínguez‐Vega, E., Fang, F., Fillet, M., Fischer, M. S., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202518366 · Cited by 16
Self-citationCrowl, S., Coleman, M. B., Chaphiv, A., Jordan, B. T., & Naegle, K. M. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101318 · Cited by 10
Diving deeper into the proteome
Seydel, C. (2022) · Nature Methods · doi:10.1038/s41592-022-01599-9 · Cited by 11
Jamwal, S., Jena, M. K., Tyagi, N., Kancharla, S., Kolli, P., Mandadapu, G., Kumar, S., & Mohanty, A. K. (2023) · Journal of Developmental Biology · doi:10.3390/jdb12010002 · Cited by 11
“…of RNA transcripts), metabolomics (global profiling of metabolites), and lipidomics (global profiling of lipids) [12] Proteins are the primary functional biomolecules of cells [13], and the expression and state of proteins give rise to different physiological processes at the cellular level [14].”
BackgroundToward a hypothesis‐free understanding of how phosphorylation dynamically impacts protein turnover
Li, W., Šalovská, B., Fornasiero, E. F., & Liu, Y. (2022) · PROTEOMICS · doi:10.1002/pmic.202100387 · Cited by 9
“As such one important future development for this field is to combine the peptidoform level measurements with approaches that provide information at the level of the whole protein polypeptide by using, for example, topdown proteomics [75].”
Background(2024) · doi:10.1016/j.mcpro.2024.100820 · Cited by 10
Post-Translationally Modified Proteoforms as Biomarkers: From Discovery to Clinical Use
Luo, Y. R., Yeung, P. S.-W., Mann, M. W., Zhang, L., Yang, Y. K., & Hoofnagle, A. N. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf094 · Cited by 15
Askarani, M. F., Fang, F., Counts, S., & Sun, L. (2025) · PROTEOMICS · doi:10.1002/pmic.70041 · Cited by 12
Proteomics approaches – their potential for answering complex questions in meat science research
Huff-Lonergan, E. J., & Lonergan, S. M. (2023) · Italian Journal of Animal Science · doi:10.1080/1828051x.2023.2248182 · Cited by 10
“The term ‘ proteoform ’ has been proposed to refer to all the different forms a protein from one gene can be found to exist in (Smith et al. 2013, 2019, 2021).”
BackgroundMass spectrometry-based proteomics for advancing solid organ transplantation research
Huang, C., Su, P., Fisher, T. D., Levitsky, J., Kelleher, N. L., & Forte, E. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1286881 · Cited by 11
Self-citationMapping the Multiscale Proteomic Organization of Cellular and Disease Phenotypes
Cesnik, A. J., Schaffer, L. V., Gaur, I., Jain, M., Ideker, T., & Lundberg, E. K. (2024) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-102423-113534 · Cited by 11
“…maps and parts lists have been refined,including the recently completed telomere-to-telomere genome (41), the creation of inventories of proteomes (42, 43) and transcriptomes (33, 44, 45) across diverse cell types, and ongoing efforts to identify all human proteoforms in many cell types (46, 47).”
BackgroundFornelli, L., Ayoub, D., Srzentić, K., Nagornov, K. O., Kozhinov, A. N., Gasilova, N., Menin, L., Beck, A., & Tsybin, Y. O. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.114 · Cited by 13
Self-citationChatterjee, S., & Zaia, J. (2022) · Mass Spectrometry Reviews · doi:10.1002/mas.21813 · Cited by 11
Clinical application of serum-based proteomics technology in human tumor research
Li, C., Xiao, J., Wu, S., Liu, L., Zeng, X., Zhao, Q., & Zhang, Z. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2022.115031 · Cited by 9
Thibault, E., & Brandizzí, F. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231025 · Cited by 8
Metadata
- Authors
- Smith, L. M., Agar, J. N., Chamot-Rooke, J., Danis, P. O., Ge, Y., Loo, J. A., Paša-Tolić, L., Tsybin, Y. O., Kelleher, N. L., & The Consortium for Top-Down Proteomics
- Affiliations
- University of Wisconsin–Madison (US)
- Northeastern University (US)
- Department of Structural Biology and Chemistry, Institut Pasteur, CNRS, Paris, France.
- Consortium for Top-Down Proteomics, Cambridge, MA, USA.
- University of California, Los Angeles (US)
- Pacific Northwest National Laboratory, Richland, WA, USA.
- Spectroswiss (Switzerland) (CH)
- Northwestern University (US)
- Corresponding author
- Kelleher, Neil L.
- ORCID
- Venue
- Science Advances
- Published
- 2021-11-12
- Volume
- 7
- Issue
- 46
- Pages
- eabk0734-eabk0734
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC8589312
- OpenAlex
- W3212853007
- Semantic Scholar
- ec7918066a2371daeda68b271a36d2b5dc582e6d
- Cited by
- 242
- References
- 49
- Citations by year
- 2026: 43 · 2025: 51 · 2024: 51 · 2023: 52 · 2022: 39 · 2021: 6
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Science Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- U.S. Department of Energy (DE-AC05–76RL01830, 76RL01830, AC05-76RL01830, DE-AC05?, DEFC0202ER63421, FC02-02ER63421)
- Centre National de la Recherche Scientifique
- National Institutes of Health (DE-FC02-02ER63421, UL1TR001422, HL096971, DE-AC05-76RL01830)
- Office of Science (02ER63421, DEFC0202ER63421, DE‐AC05‐76 RL01830)
- National Heart, Lung, and Blood Institute (R01HL096971)
- National Cancer Institute (UG3CA256959)
- National Institute of General Medical Sciences (P41GM108569, GM117058, R01GM103479, GM125085, R01GM125085, R01GM117058, R35GM126914)
- National Center for Advancing Translational Sciences
- Biological and Environmental Research (DE-AC05-76 RL01830, DE‐FC02‐02ER63421, AC05-76RL01830, 76RL01830)
- Common Fund
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Keywords
- human proteome, proteoforms, post-translational modification, genetic polymorphism, disease research, proteomics technologies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.